Biotech | August 09, 2021
AstraZeneca Pharma India PAT at Rs 10.24 crores
Board declares interim dividend of Rs 2 per equity share
Board declares interim dividend of Rs 2 per equity share
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The data should be submitted by August 12th 2021
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
Subscribe To Our Newsletter & Stay Updated
